Gastric carcinoma is one of the most common carcinomas and a leading cause of death from cancer in Turkey, The relationship between clinicopathological features of the disease and oncogenes is under investigation. In this retrospective study we investigated the relationships between expression of c-erbB-2 oncoprotein and grade, stage and pathological characteristics of the tumour, and prognosis. Formalin-fixed, paraffin-embedded tissue sections were prepared from gastrectomy specimens from 55 patients with gastric carcinoma. The tissue sections were stained immunohistochemically to reveal c-erbB-2 protein. Six (10%) of the tumours stained positively for c-erbB-2 protein.
There was no statistically significant association (P > 0.5) between c-erbB-2 staining and tumour grade, stage or pathological characteristics (necrosis, lymph-node infiltration), or between staining and prognosis. The results suggest that overexpression of c-erb-B-2 protein is not related to the pathological characteristics of the tumour in gastric carcinoma and is not an important prognostic indicator.
INTRODUCTION
Gastric cancer is the fifth most common cancer in both men and women, and the fourth most common cause of death from 74 cancer in the world. Gastric cancer is the second most common cause of cancer death in men and women in Turkey. The early S Giirel, E Dolar; (j Yerci et at.
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diagnosis and surgical treatment of gastric cancer may decrease the mortality rate associated with this malignancy. The prognosis in patients with gastric cancer depends on the time of diagnosis and is influenced by clinical and pathological variables, including age of onset, gastric-wall invasion, extent of spread of disease, and lymph-node involvement.' The prognosis of advanced gastric cancer is still poor and treatment is usually unsuccessful. Gastric cancer in the advanced stage is generally considered incurable, but the role of palliative chemotherapy and radiotherapy is becoming more accepted. Validated prognostic markers for gastric cancer need to be found. Many studies have investigated gastric cancer at the genetic level and found genetic alterations, including overexpression of c-erbB-2 protein." The human c-erbB-2 gene is an oncogene encoding a 185-kDa glycoprotein with protein-tyrosine kinase activity, and is homologous to the epidermal growth factor receptor gene." Some investigators reported that overexpression of the c-erbB-2 oncoprotein was associated with the histopathological type of gastric adenocarcinoma: overexpression was found in 40% oftubular-type adenocarcinomas but not in the signet-ring-cell type!
The aim of this study was to investigate the relationship between c-erbB-2 oncoprotein expression and the clinicopathological factors that can affect disease prognosis in gastric carcinoma.
MATERIALS AND METHODS

SPECIMENS
In this retrospective study we examined gastrectomy specimens from 55 consecutive patients with gastric carcinoma (32 men and 23 women; mean age 55 years ± SE; range, 20 -80 years). All patients had been 75 diagnosed in the Medical School of Uludag University Department of Gastroenterology, and treated in the Department of General Surgery. Each had undergone gastrectomy or partial gastrectomy, combined with lymphnode dissection, between 1994 and 1998.
DETECTION OF c-ERBB-2 PROTEIN
The specimens were fixed in 10% formalin for a minimum of 10 h and then embedded in paraffin. The paraffin-embedded tissue sections were sliced into sections 5-11m thick and immunostained as described below. Deparaffinized sections were immersed in 0.3% peroxidase solution, washed in water, and then incubated with monoclonal antibodies.
An immunohistochemical staining method (DAKO, Rabbit Anti-human) was used to bind to the monoclonal antibodies and reveal the c-erbB-2 protein.
The same pathologist examined all of the tissue sections to evaluate staining. The histopathological type of the tumour, depth of invasion, extent oflymph-node metastasis, and tumour location were assessed by other pathologists in the Pathology Department.
STATISTICAL ANALYSIS
Differences between the positively and negatively immunostaining groups with regard to clinicopathological parameters were analysed statistically by the Mann-Whitney V-test and the survival curves were drawn using the Kaplan-Meier method and analysed by the log-rank test. P-values < 0.05 were considered to be statistically significant.
RESULTS
Of the 55 tumours, six (10%) stained positively for c-erbB-2 protein (Fig. 1) , the other 49 (90%) tumours stained negatively. There was no significant association between c-erbB-2 protein staining and the age or S Giird, E Dohn: (j l"en:i et aI.
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FIGURE 1
Immunohistochemical staining of c-erbB-2 protein (dark areas) in a section of gastric carcinoma (original magnification multi x 200)
gender of the patient, or the grade, extent of wall invasion, pathological type or characteristics of the tumour including necrosis, lymph-node infiltration or perineural invasion (Table 1) .
There was also no significant association between c-erbB-2 staining and prognosis. Survival curves of patients with gastric tumours with positive and negative c-erbB-2 staining are shown in Fig. 2 . The mean survival time was 23 months in patients with tumours staining positively for c-erbB-2 protein, and 21 months in patients whose tumours stained negatively (P> 0.05).
DISCUSSION
The incidence of positive staining for c-erbB-2 protein observed in the present study (10%) 55 patients with gastric carcinoma,   comparing c-erbB-2-negative f-, n = 49) and c-erbB-2-positive(----, n = 6) tumours.
Kaplan-Meier plot for cumulative survival in
S Giirel, E DoJar, 0 Yerci et al. There were no statistically significantdifferences between the positively and negativelystaining groups (Mann-Whitney U-test; log-rank test for the survival data). SE, standard error.
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is similar to that observed in other studies on gastric cancer." - 7 Overexpression of c-erbB-2 protein is known to be one of the most important prognostic factors in breast cancer.v" and we thought that a similar association might be present in gastric cancer. The depth of tumour invasion and extent of lymph-node metastasis are already known to be prognostic indicators in gastric cancer. to We investigated the relationship between c-erbB-2 protein expression and clinicopathological characteristics of gastric carcinoma, but we could not demonstrate a statistically significant difference in survival curves 77 between the group of patients with positively staining tumours and the group with negatively staining tumours. The results indicate that overexpression of c-erbB-2 protein might not be a prognostic factor in gastric carcinoma. We could not find a relationship between c-erbB-2 protein staining and the pathological characteristics of the tumour (necrosis, lymph-node infiltration, depth of tumour invasion, invasion of vessels, or grade of disease).
In contrast to the views reported in some of the literature , 11 we conclude that c-erbB-2 protein expression is not a good predictor of prognosis in gastric carcinoma. Additional S Giirel, E Dolar, 0 Yerci et al.
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in gastric carcinoma studies that include large numbers of patients are necessary, however, to confirm whether or not c-erbB-2 oncoprotein
